Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer

At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.

Euro coins stacked like a king on a chess board

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Dec. 12-Jan. 3. Deal Watch is supported by deal intelligence from Strategic Transactions.

Sanofi Pasteur MSD – the joint venture in Europe between Sanofi's vaccine arm and Merck & Co....

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.